MRSN - Mersana Therapeutics Inc
IEX Last Trade
1.57
0.050 3.185%
Share volume: 479,849
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.52
0.05
3.29%
View ratios
Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
Report Date | 2022-08-08 | 2022-11-07 | 2023-02-28 | 2023-05-09 | 2023-08-08 | 2023-11-07 | 2024-02-28 | 2024-05-09 | |
Total revenue | 4.284 M | 5.573 M | 14.688 M | 7.802 M | 10.654 M | 7.698 M | 10.701 M | 9.245 M | |
Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Gross profit | 4.284 M | 5.573 M | 14.688 M | 7.802 M | 10.654 M | 7.698 M | 10.701 M | 9.245 M | |
30.09% | 163.56% | -46.88% | 36.55% | -27.75% | 39.01% | -13.61% | |||
Operating expenses | 56.034 M | 65.212 M | 60.514 M | 65.603 M | 67.155 M | 43.425 M | 31.629 M | 30.246 M | |
Selling general and admin | 14.803 M | 14.573 M | 14.805 M | 18.328 M | 18.187 M | 12.894 M | 10.134 M | 11.560 M | |
Research and development | 41.231 M | 50.639 M | 45.709 M | 47.275 M | 48.968 M | 30.531 M | 21.495 M | 18.686 M | |
Total expenses | 56.034 M | 65.212 M | 60.514 M | 65.603 M | 67.155 M | 43.425 M | 31.629 M | 30.246 M | |
16.38% | -7.20% | 8.41% | 2.37% | -35.34% | -27.16% | -4.37% | |||
Operating income | -51.750 M | -59.639 M | -45.826 M | -57.801 M | -56.501 M | -35.727 M | -20.928 M | -21.001 M | |
Ebit | -51.750 M | -59.639 M | -45.826 M | -57.801 M | -56.501 M | -35.727 M | -20.928 M | -21.001 M | |
Pretax income | -52.219 M | -59.811 M | -44.924 M | -56.163 M | -54.307 M | -41.656 M | -19.544 M | -19.306 M | |
14.54% | -24.89% | 25.02% | -3.30% | -23.30% | -53.08% | -1.22% | |||
Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Net income basic | -52.219 M | -59.811 M | -44.924 M | -56.163 M | -54.307 M | -41.656 M | -19.544 M | -19.306 M | |
-14.54% | 24.89% | -25.02% | 3.30% | 23.30% | 53.08% | 1.22% | |||
Net income | -52.219 M | -59.811 M | -44.924 M | -56.163 M | -54.307 M | -41.656 M | -19.544 M | -19.306 M | |
-14.54% | 24.89% | -25.02% | 3.30% | 23.30% | 53.08% | 1.22% |